Drug Discovery & DevelopmentGSK, J&J develop single-pill HIV medicineThe Star-LedgerGlaxoSmithKline Plc and Johnson & Johnson will develop a new HIV medicine that combines two drugs to take on industry leader Gilead Sciences Inc. Glaxo’s majority-owned ViiV Healthcare venture is collaborating with Johnson & Johnson’s Janssen unit to …J&J teams with Glaxo’s ViiV on an HIV combo treatmentFierceBiotechViiV to Collaborate with Janssen on HIV Drug ComboDrug Discovery & DevelopmentJ&J links up with GSK-led group on new two-drug HIV tabletReutersRTT News -MarketWatch -Businessweekall 25 news articles …Read Full Story
GSK, J&J develop single-pill HIV medicine - The Star-Ledger
Real Estate of Cebu
